Neoantigen-driven B cell and CD4+ T follicular helper cell collaboration promotes robust anti-tumor CD8+ T cell responses
C. Cui, J. Wang, P.-M. Chen, K. A. Connolly, M. Damo, E. Fagerberg, S. Chen, S. C. Eisenbarth, H. Zhao, J. Craft, N. S. Joshi
Abstract
CD4+ T follicular helper (TFH) cells provide help to B cells, which is critical for germinal center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We found TFH cells correlated with GC B cells and with prolonged survival of lung adenocarcinoma (LUAD) patients. To investigate further, we developed an LUAD model, in which tumor cells expressed B-cell- and T-cell-recognized neoantigens. Interactions between tumor-specific TFH and GC B cells were necessary for tumor control, as were effector CD8+ T cells. The latter were reduced in the absence of T cell-B cell interactions or the IL-21 receptor. IL-21 was produced primarily by TFH cells, development of which required B cells. Moreover, development of tumor-specific TFH cell-responses was also reliant upon tumors that expressed B-cell-recognized neoantigens. Thus, tumor-neoantigens themselves can control the fate decisions of tumor-specific CD4+ T cells by facilitating interactions with tumor-specific B cells. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=115 SRC="FIGDIR/small/424168v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@f31b57org.highwire.dtl.DTLVardef@881959org.highwire.dtl.DTLVardef@1385ccdorg.highwire.dtl.DTLVardef@154ba3b_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CD4+ follicular helper-like T cells are key players in anti-tumor immunity
D. Singh, A. P. Ganesan, … P. Vijayanand·bioRxiv·Jan 8, 2020
- B cells sustain tumor-specific CD4 T cells to promote response to PD-1 targeted therapy
Abishek Balachandra Vaidya, Étienne Humblin, … Alice Oliffson Kamphorst·bioRxiv·Sep 24, 2026
- Systemic neoantigen-specific T cells reveal central determinants of PD-(L)1 blockade efficacy
Célia Ramade, Noémie Thébault, … Maha Ayyoub·bioRxiv·Mar 12, 2026
- The spontaneous neoantigen-specific CD4+ T cell response to a growing tumor is functionally and phenotypically diverse.
Ryan Q. Griswold, Spencer E. Brightman, … Stephen Philip Schoenberger·Journal for ImmunoTherapy of CancerPeer-reviewed·Sep 1, 2025
- Common origin for effector and regulatory Follicular and Tissue-Adapted CD4+ T cells in Non-Small Cell Lung Cancer
Jimena Tosello, Wilfrid Richer, … Eliane Piaggio·bioRxiv·Sep 17, 2025
- A single MHCII neoepitope mRNA vaccine elicits CD4 T- and B- cell responses promoting endogenous CD8 anti-tumor immunity
Aude-Hélène Capietto, Camille-Charlotte Balança, … Jonathan L. Linehan·bioRxiv·Jun 9, 2025